Bull&Bear | Chimerix and UniQure Lead Bullish Surge Amid FDA Developments; TScan and Intellinetics Face Bearish Pressure

In the realm of bullish stocks, several companies have made notable gains. Chimerix (CMRX) surged by 219.08% and has risen for two consecutive days, accumulating a total increase of 231.73% over the past two days. This comes as Chimerix is preparing to submit an application for accelerated approval to the U.S. FDA for Dordaviprone, aimed at treating patients with recurrent H3 K27M mutant diffuse glioma by the end of the year.

UniQure (QURE) experienced a substantial increase of 109.73%. This surge follows the company receiving an upgraded rating due to its agreement reached with the FDA.

Roadzen (RDZN) marked a 57.58% increase and has seen an impressive nine-day continuous rise, totaling a 161.57% gain over this period. Roadzen announced that a major liquefied natural gas supplier in India will equip its entire truck fleet with Roadzen's DrivebuddyAI. The five-year contract involves more than 500 vehicles and is expected to generate revenue in the seven-figure range over its duration.

Cardiff Oncology (CRDF) saw a 54.92% increase, continuing its upward trend for two days with a total gain of 63.64%. The rise in Cardiff Oncology's shares is attributed to preliminary positive results from its colon cancer trials.

Troops Inc. (TROO) climbed by 50.65%, marking two consecutive days of gains with an overall increase of 51.63% in that span. The company's shares surged following the release of its foreign issuer report, showcasing its latest performance metrics.

In contrast, bearish stocks saw notable declines. TScan Therapeutics (TCRX) dropped by 28.23%. The company plans to hold a virtual KOL event to discuss clinical updates from its ALLOHA Phase I trial and its hematology development strategy.

Intellinetics, Inc. (XCH) faced a decline of 21.17%, marking it as the largest drop among Chinese concept stocks, with an overall fall of 24.81%.

Esperion Therapeutics (ESPR) decreased by 20.63%, though no severe adverse events were observed in its phenylpropylic acid trials.

Genasys (GNSS) saw its stock drop by 20.00% following the company’s report of a year-over-year decrease in fourth-quarter revenues.

Graphjet Technology (GTI) experienced an 18.93% decline over two consecutive days, accumulating a total decrease of 39.71%. The company recently announced the appointment of Liu Yu as its Chief Operating Officer and Chief Scientific Officer.